期刊
AMERICAN JOURNAL OF PSYCHIATRY
卷 159, 期 9, 页码 1596-1598出版社
AMER PSYCHIATRIC PRESS, INC
DOI: 10.1176/appi.ajp.159.9.1596
关键词
-
类别
Objective. The study investigated the efficacy and tolerability of ethyl-eicosapentaenoic acid (E-EPA) as add-on treatment in chronic, severe schizophrenia. Method: A randomized, parallel-group, double-blind, placebo-controlled, fixed-dose, add-on study was conducted over 12 weeks. Forty patients with persistent symptoms after at least 6 months of stable antipsychotic treatment received E-EPA or placebo, in addition to their existing treatment. Results. At 12 weeks, the E-EPA group had significantly greater reduction of Positive and Negative Syndrome Scale total scores and of dyskinesia scores than the placebo group. Conclusions: EPA may be an effective and well-tolerated add-on treatment in schizophrenia.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据